丽人丽妆(605136) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥345,664,992.29, representing a year-on-year increase of 32.55%[4] - The total profit for Q3 2025 was a loss of ¥1,785,561.06, while the net profit attributable to shareholders was a loss of ¥3,732,443.30[4] - Year-to-date revenue as of Q3 2025 was ¥1,176,682,888.68, showing a decline of 4.09% compared to the same period last year[4] - The company experienced a decrease in net profit attributable to shareholders for the year-to-date period, primarily due to a decline in overall operating revenue and increased asset impairment losses[9] - Net profit for the first three quarters of 2025 was a loss of CNY 37,479,740.52, compared to a loss of CNY 29,116,284.23 in 2024, representing a 28.7% increase in losses[19] - Earnings per share for the first three quarters of 2025 was CNY -0.09, compared to CNY -0.07 in the same period of 2024[20] - The company reported a total comprehensive loss of CNY 38,121,312.60 for the first three quarters of 2025, compared to a loss of CNY 30,502,059.20 in 2024[20] Cash Flow - The net cash flow from operating activities for the year-to-date period was a negative ¥12,179,913.08, reflecting a decrease of 103.10%[5] - Cash inflow from operating activities for the first three quarters of 2025 was CNY 1,495,270,455.61, a decrease of 22.5% from CNY 1,928,225,260.17 in 2024[22] - Cash received from sales of goods and services was CNY 1,324,693,130.29, down from CNY 1,429,344,168.04 in the previous year[22] - The net cash flow from operating activities was -$12.18 million, a significant decrease compared to $393.16 million in the previous period[23] - The company reported a total cash outflow from operating activities of $1.51 billion, slightly lower than $1.54 billion in the previous period[23] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥2,594,850,868.54, down 5.61% from the end of the previous year[5] - The equity attributable to shareholders at the end of Q3 2025 was ¥2,447,228,432.65, a decrease of 1.49% from the previous year[5] - As of September 30, 2025, the company's total assets amounted to CNY 2,594,850,868.54, a decrease from CNY 2,748,938,027.69 as of December 31, 2024[14] - The company's cash and cash equivalents decreased to CNY 649,081,257.74 from CNY 833,765,764.39 year-over-year[14] - The total current liabilities decreased significantly to CNY 151,409,506.24 from CNY 261,185,420.31 in the previous year[16] - The company's inventory decreased to CNY 352,367,990.61 from CNY 435,666,051.57 year-over-year[15] - The company's long-term equity investments decreased to CNY 6,796,287.94 from CNY 8,979,311.89 year-over-year[15] - The company's total non-current liabilities decreased to CNY 4,410,593.60 from CNY 10,600,526.09 year-over-year[16] - The company's accounts receivable decreased to CNY 41,703,459.69 from CNY 51,312,892.08 year-over-year[14] - The company reported a significant increase in other receivables, totaling CNY 152,275,088.44 compared to CNY 164,834,832.97 in the previous year[15] Strategic Developments - The company's self-owned brand and general agency business grew rapidly, accounting for nearly 15% of total revenue in the first three quarters of 2025[13] - The company entered into a strategic partnership with ENDOCARE, becoming the brand's general agent in mainland China, responsible for brand promotion and market operations[13] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 16,574,954.98, slightly down from CNY 17,715,212.00 in 2024[18] Other Income - The company reported non-recurring gains of ¥19,605,893.77 for the current period, with government subsidies contributing ¥23,677,467.71[7] - Other income for the first three quarters of 2025 was CNY 24,620,305.36, an increase from CNY 19,342,129.12 in 2024[18]